Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

BACKGROUND: Thrombocytopenia in patients with myelodysplastic syndrome (MDS) is associated with shortened survival and an increased risk of evolution to acute myeloid leukemia (AML). In this study, the authors evaluated the efficacy of romiplostim in patients who had thrombocytopenia with low-risk/i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer
Auteurs principaux: Giagounidis, Aristoteles, Mufti, Ghulam J, Fenaux, Pierre, Sekeres, Mikkael A, Szer, Jeffrey, Platzbecker, Uwe, Kuendgen, Andrea, Gaidano, Gianluca, Wiktor-Jedrzejczak, Wieslaw, Hu, Kuolung, Woodard, Paul, Yang, Allen S, Kantarjian, Hagop M
Format: Artigo
Langue:Inglês
Publié: BlackWell Publishing Ltd 2014
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4298760/
https://ncbi.nlm.nih.gov/pubmed/24706489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28663
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires